BACKGROUND: Viral respiratory infection (VRI) is a common cause of pulmonary exacerbations in children with cystic fibrosis (CF). The importance of VRI in adult CF populations is unclear. OBJECTIVE: To determine the incidence and clinical impact of VRI among adults with CF. METHODS: One hundred adults with CF were followed up prospectively for 12 months. Sputum, nose swabs and throat swabs were collected every 2 months and at onset of pulmonary exacerbation. PCR assays for adenovirus, influenza A&B, human metapneumovirus, parainfluenza 1-3, respiratory syncytial virus and human rhinovirus were performed on each sample. Symptom scores, spirometry and inflammatory markers were measured at each visit. RESULTS: One or more respiratory viruses were detected in 191/626 (30.5%) visits. Human rhinovirus accounted for 72.5% of viruses. Overall incidence of VRI was 1.66 (95% CI 1.39 to 1.92) cases/patient-year. VRI was associated with increased risk of pulmonary exacerbation (OR=2.19; 95% CI 1.56 to 3.08; p<0.001) and prescription of antibiotics (OR=2.26; 95% CI 1.63 to 3.13; p<0.001). Virus-positive visits were associated with higher respiratory symptom scores and greater C-reactive protein levels. Virus-positive exacerbations had a lower acute fall in FEV1 than virus-negative exacerbations (12.7% vs 15.6%; p=0.040). The incidence of exacerbations, but not VRI, was associated with greater lung function decline over 12 months (-1.79% per pulmonary exacerbation/year; 95% CI -3.4 to -0.23; p=0.025). CONCLUSION: VRI is common in adults with CF and is associated with substantial morbidity. Respiratory viruses are a potential therapeutic target in CF lung disease.
BACKGROUND:Viral respiratory infection (VRI) is a common cause of pulmonary exacerbations in children with cystic fibrosis (CF). The importance of VRI in adult CF populations is unclear. OBJECTIVE: To determine the incidence and clinical impact of VRI among adults with CF. METHODS: One hundred adults with CF were followed up prospectively for 12 months. Sputum, nose swabs and throat swabs were collected every 2 months and at onset of pulmonary exacerbation. PCR assays for adenovirus, influenza A&B, human metapneumovirus, parainfluenza 1-3, respiratory syncytial virus and human rhinovirus were performed on each sample. Symptom scores, spirometry and inflammatory markers were measured at each visit. RESULTS: One or more respiratory viruses were detected in 191/626 (30.5%) visits. Human rhinovirus accounted for 72.5% of viruses. Overall incidence of VRI was 1.66 (95% CI 1.39 to 1.92) cases/patient-year. VRI was associated with increased risk of pulmonary exacerbation (OR=2.19; 95% CI 1.56 to 3.08; p<0.001) and prescription of antibiotics (OR=2.26; 95% CI 1.63 to 3.13; p<0.001). Virus-positive visits were associated with higher respiratory symptom scores and greater C-reactive protein levels. Virus-positive exacerbations had a lower acute fall in FEV1 than virus-negative exacerbations (12.7% vs 15.6%; p=0.040). The incidence of exacerbations, but not VRI, was associated with greater lung function decline over 12 months (-1.79% per pulmonary exacerbation/year; 95% CI -3.4 to -0.23; p=0.025). CONCLUSION:VRI is common in adults with CF and is associated with substantial morbidity. Respiratory viruses are a potential therapeutic target in CF lung disease.
Authors: William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam Journal: J Clin Microbiol Date: 2015-04-15 Impact factor: 5.948
Authors: W G Flight; R J Bright-Thomas; C Sarran; K J Mutton; J Morris; A K Webb; A M Jones Journal: Int J Biometeorol Date: 2014-01-23 Impact factor: 3.787
Authors: Abigail R Berkebile; Jennifer A Bartlett; Mahmoud Abou Alaiwa; Steven M Varga; Ultan F Power; Paul B McCray Journal: Am J Respir Cell Mol Biol Date: 2020-01 Impact factor: 6.914
Authors: Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir Journal: ERJ Open Res Date: 2022-05-23
Authors: Deepika Polineni; Hong Dang; Paul J Gallins; Lisa C Jones; Rhonda G Pace; Jaclyn R Stonebraker; Leah A Commander; Jeanne E Krenicky; Yi-Hui Zhou; Harriet Corvol; Garry R Cutting; Mitchell L Drumm; Lisa J Strug; Michael P Boyle; Peter R Durie; James F Chmiel; Fei Zou; Fred A Wright; Wanda K O'Neal; Michael R Knowles Journal: Am J Respir Crit Care Med Date: 2018-01-01 Impact factor: 21.405
Authors: Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie Journal: Clin Transl Sci Date: 2015-12-08 Impact factor: 4.689
Authors: Sara Khanal; Megan Webster; Naiqian Niu; Jana Zielonka; Myra Nunez; Geoffrey Chupp; Martin D Slade; Lauren Cohn; Maor Sauler; Jose L Gomez; Robert Tarran; Lokesh Sharma; Charles S Dela Cruz; Marie Egan; Theresa Laguna; Clemente J Britto Journal: Eur Respir J Date: 2021-11-11 Impact factor: 33.795